Eric Wenzler

2.2k total citations
80 papers, 1.5k citations indexed

About

Eric Wenzler is a scholar working on Molecular Medicine, Pharmacology and Epidemiology. According to data from OpenAlex, Eric Wenzler has authored 80 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Medicine, 40 papers in Pharmacology and 24 papers in Epidemiology. Recurrent topics in Eric Wenzler's work include Antibiotic Resistance in Bacteria (41 papers), Antibiotics Pharmacokinetics and Efficacy (39 papers) and Bacterial Identification and Susceptibility Testing (18 papers). Eric Wenzler is often cited by papers focused on Antibiotic Resistance in Bacteria (41 papers), Antibiotics Pharmacokinetics and Efficacy (39 papers) and Bacterial Identification and Susceptibility Testing (18 papers). Eric Wenzler collaborates with scholars based in United States, United Kingdom and Japan. Eric Wenzler's co-authors include Mark Biagi, Keith A. Rodvold, Larry H. Danziger, David A. Butler, Amanda Harrington, Zackery P. Bulman, Xing Tan, Shitalben Patel, Debra A. Goff and Dustin R. Fraidenburg and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Clinical Microbiology Reviews.

In The Last Decade

Eric Wenzler

78 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Wenzler United States	24	872	636	444	393	284	80	1.5k
Thomas Tängdén Sweden	22	1.0k 1.2×	550 0.9×	516 1.2×	371 0.9×	295 1.0×	64	1.8k
Andrew Denisuik Canada	11	1.2k 1.3×	704 1.1×	515 1.2×	349 0.9×	215 0.8×	19	1.4k
Anthony Harris United States	14	1.1k 1.2×	439 0.7×	467 1.1×	511 1.3×	303 1.1×	24	1.5k
Melanie Baxter Canada	24	841 1.0×	448 0.7×	679 1.5×	291 0.7×	182 0.6×	76	1.6k
Giusy Tiseo Italy	22	890 1.0×	539 0.8×	533 1.2×	483 1.2×	165 0.6×	62	1.6k
Angela Gomez‐Simmonds United States	21	1.1k 1.2×	412 0.6×	419 0.9×	322 0.8×	388 1.4×	34	1.7k
Elizabeth Neuner United States	20	793 0.9×	517 0.8×	612 1.4×	335 0.9×	155 0.5×	53	1.4k
Flora Kontopidou Greece	16	1.2k 1.4×	759 1.2×	558 1.3×	347 0.9×	235 0.8×	29	1.6k
Isabel Machuca Spain	17	750 0.9×	342 0.5×	320 0.7×	297 0.8×	189 0.7×	43	1.2k
Sibylle Lob United States	27	1.4k 1.6×	780 1.2×	543 1.2×	686 1.7×	291 1.0×	61	1.8k

Countries citing papers authored by Eric Wenzler

Since Specialization

Citations

This map shows the geographic impact of Eric Wenzler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Wenzler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Wenzler more than expected).

Fields of papers citing papers by Eric Wenzler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Wenzler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Wenzler. The network helps show where Eric Wenzler may publish in the future.

Co-authorship network of co-authors of Eric Wenzler

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Wenzler. A scholar is included among the top collaborators of Eric Wenzler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Wenzler. Eric Wenzler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tao, Lili, et al.. (2024). Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli. Antimicrobial Agents and Chemotherapy. 68(10). e0069324–e0069324. 4 indexed citations

Quigley, John G., et al.. (2023). Comparison of thrombotic and clinical outcomes in SARS-CoV-2-pneumonia versus other viral pneumonia in an urban academic medical center. Heart & Lung. 61. 153–157. 1 indexed citations

Wenzler, Eric, et al.. (2023). Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19. International Journal of Antimicrobial Agents. 62(3). 106920–106920. 1 indexed citations

Tao, Lili, Emily Jacobs, Yehudit Bergman, et al.. (2023). Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test. Journal of Clinical Microbiology. 61(5). e0164722–e0164722. 20 indexed citations

Wenzler, Eric, et al.. (2023). Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 43(4). 264–278. 25 indexed citations

Moore, Luke, María Virginia Villegas, Eric Wenzler, et al.. (2023). Rapid Diagnostic Test Value and Implementation in Antimicrobial Stewardship Across Low-to-Middle and High-Income Countries: A Mixed-Methods Review. Infectious Diseases and Therapy. 12(6). 1445–1463. 10 indexed citations

Biagi, Mark, et al.. (2022). Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales. Diagnostic Microbiology and Infectious Disease. 103(2). 115674–115674. 12 indexed citations

Tamma, Pranita D., Patrick N. A. Harris, Amy J. Mathers, Eric Wenzler, & Romney M. Humphries. (2022). Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales. Clinical Infectious Diseases. 77(11). 1585–1590. 22 indexed citations

Wenzler, Eric, et al.. (2022). The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A review. Frontiers in Pharmacology. 13. 888079–888079. 23 indexed citations

10.

Tan, Xing, Kimberly Baugh, Yanqin Huang, et al.. (2021). Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales. Infection and Drug Resistance. Volume 14. 125–142. 74 indexed citations

11.

Bulman, Zackery P., Fiorella Krapp, Nathan B. Pincus, et al.. (2021). Genomic Features Associated with the Degree of Phenotypic Resistance to Carbapenems in Carbapenem-Resistant Klebsiella pneumoniae. mSystems. 6(5). e0019421–e0019421. 32 indexed citations

12.

Huang, Yanqin, Eric Wenzler, Egon A. Ozer, et al.. (2021). Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. 77(2). 356–363. 19 indexed citations

13.

Wenzler, Eric, Maressa Santarossa, Kevin A. Meyer, et al.. (2020). In Vitro Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant Enterococcus faecium and Carbapenem-Resistant Enterobacter cloacae Bacteremia in a Liver Transplant Patient. Open Forum Infectious Diseases. 7(1). ofz545–ofz545. 6 indexed citations

14.

Biagi, Mark, et al.. (2020). Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy. 64(12). 36 indexed citations

15.

Gerlach, Anthony T., et al.. (2019). Pharmacokinetic/pharmacodynamic predictions and clinical outcomes of patients with augmented renal clearance and Pseudomonas aeruginosa bacteremia and/or pneumonia treated with extended infusion cefepime versus extended infusion piperacillin/tazobactam. International Journal of Critical Illness and Injury Science. 9(3). 138–138. 6 indexed citations

16.

Butler, David A., et al.. (2019). Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat. Current Infectious Disease Reports. 21(12). 46–46. 52 indexed citations

17.

Wenzler, Eric, et al.. (2018). Clinical use of the polymyxins: the tale of the fox and the cat. International Journal of Antimicrobial Agents. 51(5). 700–706. 8 indexed citations

18.

Wenzler, Eric, Susan C Bleasdale, Monica K Sikka, et al.. (2018). Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. Antimicrobial Agents and Chemotherapy. 62(8). 20 indexed citations

19.

Wenzler, Eric, et al.. (2017). Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease. 90(4). 335–336. 5 indexed citations

20.

Wenzler, Eric, Debra A. Goff, Julie E. Mangino, et al.. (2015). Impact of rapid identification of Acinetobacter Baumannii via matrix-assisted laser desorption ionization time-of-flight mass spectrometry combined with antimicrobial stewardship in patients with pneumonia and/or bacteremia. Diagnostic Microbiology and Infectious Disease. 84(1). 63–68. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact